Long-term outcomes after treatment of in-stent restenosis using the Absorb everolimus-eluting bioresorbable scaffold.

ABSTRACT: Early studies evaluating the performance of bioresorbable scaffold (BRS) Absorb in in-stent restenosis (ISR) lesions indicated promising short-term to mid-term outcomes. To evaluate long-term outcomes (up to 5 years) of patients with ISR treated with the Absorb BRS. We did an observational analysis of long-term outcomes of patients treated for ISR using the Absorb BRS (Abbott Vascular, Santa Clara, California, USA) between 2013 and 2016 at the Heart Centre Luzern. The main outcomes included a device-oriented composite endpoint (DOCE), defined as composite of cardiac death, target vessel (TV) myocardial infarction and TV revascularisation, target lesion revascularisation and scaffold thrombosis (ScT). Overall, 118 ISR lesions were treated using totally 131 BRS among 89 patients and 31 (35%)

SUBMITTER: Madanchi M 

PROVIDER: S-EPMC8438862 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature